The American Cancer Society's report provides insights into the increasing number of cancer survivors in the U.S., emphasizing the need for personalized care plans, survivorship education, and equitable access to follow-up care.
With a US manufacturing location, embecta offers a full portfolio of safety and standard (non-safety) insulin syringes to support across the continuum of care. Learn more about embecta’s portfolio of Ultra-Fine™ insulin syringes and BD SafetyGlide™ Insulin syringes. BD is the legal manufacturer of the advertised product.
Bringing together hospital and healthcare leaders for the last 17 years. If you are a healthcare leader looking to network with other healthcare & hospital leaders we hope to see you on the road in 2025!
